Delving into the Latest Updates on Axitinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Axitinib (JAN/USAN), 阿西替尼, AG-013736

+ [13]

Target

VEGFR1 x VEGFR2 x VEGFR3

Action

antagonists

Mechanism

VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)

Therapeutic Areas

NeoplasmsUrogenital DiseasesNervous System Diseases+ [7]

Active Indication

Metastatic Renal Cell CarcinomaUnresectable Renal Cell CarcinomaRenal Cell Carcinoma+ [17]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma, metastaticAdenoid Cystic Carcinoma+ [42]

Originator Organization

Pfizer Inc.

Active Organization

Ocular Therapeutix, Inc.PF Prism CVAccord Healthcare SLU

+ [11]

Inactive Organization

Merck Sharp & Dohme Corp.

AiViva BioPharma, Inc.

License Organization

Strata Oncology, Inc.

Akeso Biopharma Co., Ltd.

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

United States (27 Jan 2012),

Advanced Renal Cell Carcinoma

RegulationOrphan Drug (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H18N4OS

InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N

CAS Registry319460-85-0

This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that gut health (the gut microbiome) may impact the effectiveness of immunotherapy. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. MO-03, a type of biotherapy, contains material from living organisms that may help keep the digestive tract healthy and may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as ipilimumab, nivolumab, pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are a type of angiogenesis inhibitor and tyrosine kinase inhibitor (TKI) that block certain proteins which may help keep tumor cells from growing and may also help prevent the growth of new blood vessels that tumors need to grow. Adding MO-03 to SOC immunotherapy may be more effective than SOC immunotherapy alone in treating patients with advanced or metastatic clear cell renal cell cancer.

Start Date10 Jun 2026

Sponsor / Collaborator

SWOG

[+1]

NCT07500831

/ Not yet recruitingNot ApplicableIIT

Fasting-Mimicking Diet Combined With Toripalimab Plus Axitinib for Metastatic or Unresectable Renal Cell Carcinoma: A Single-Arm, Open-Label, Single-Center Clinical Trial

This study is testing whether adding a 5-day fasting-mimicking diet (FMD) can help people with advanced kidney cancer when given together with standard first-line cancer medicines.

Start Date01 Apr 2026

Sponsor / Collaborator

Qilu Hospital of Shandong University

NCT07469683

/ RecruitingPhase 2IIT

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

"This study is a phase 2, randomized study to evaluate the efficacy and safety of SLC-3010 in combination with axitinib versus axitinib monotherapy as second-line treatment in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
This study includes a screening period, a treatment period, and a follow-up period. All patients will complete a screening period of up to 28 days. During the treatment period, patients will receive either SLC-3010 in combination with axitinib or axitinib monotherapy. Treatment may continue until the occurrence of unacceptable toxicity related to the study intervention, patient refusal for further participation, or disease progression.
The patients will be followed up for disease progression and survival for up to 2 years after discontinuation of the study intervention, or until death, consent withdrawal, or the end of this clinical trial, whichever occurs first. For patients who withdraw consent, survival will be followed up via telephone or site visits every 2 months up to death or 12 months after the first administration of the last patient, whichever occurs first, depending on their consent for follow-up.
This study consists of two parts: Part 1 is the safety run-in phase for SLC-3010 in combination with axitinib, and Part 2 is a randomized phase 2 trial to compare SLC-3010 in combination with axitinib and axitinib monotherapy.

Start Date01 Mar 2026

Sponsor / Collaborator

Yonsei University

100 Clinical Results associated with Axitinib

Login to view more data

100 Translational Medicine associated with Axitinib

Login to view more data

100 Patents (Medical) associated with Axitinib

Login to view more data

2,557

Literatures (Medical) associated with Axitinib

01 Dec 2026·CURRENT TREATMENT OPTIONS IN ONCOLOGY

Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches

Review

Author: Chintakuntlawar, Ashish ; Hintze, Justin M

OPINION STATEMENT:

Systemic therapy for recurrent and metastatic salivary gland malignancies (SGMs) remains a major therapeutic challenge. Traditional chemotherapy offers modest response rates with limited durability, and its role is largely palliative. The most meaningful advances have occurred in biomarker-selected subgroups: androgen receptor blockade for AR-positive salivary duct carcinoma and HER2-directed therapy for HER2-positive tumors have demonstrated superior response rates and survival (often exceeding 50%), compared with the single digit response rates seen with unselected chemotherapy or tyrosine kinase inhibitors. Small-molecule tyrosine kinase inhibitors such as lenvatinib and axitinib may provide disease stabilization in adenoid cystic carcinoma, although tumor shrinkage is uncommon and toxicity limits their long-term use. Immunotherapy as a single agent has been disappointing, but durable responses in select patients and modest activity with combination regimens suggest it may have a future role when rationally paired with other agents. In our practice, comprehensive molecular profiling is essential at the time of recurrence to identify actionable alterations, prioritize targeted therapy where available, and guide clinical trial enrollment. For most patients without a targetable alteration, platinum-based combinations remain the pragmatic choice, though expectations for benefit should be tempered. Future strategies will likely hinge on optimizing biomarker-driven therapies, expanding access to antibody-drug conjugates, and pursuing collaborative trial designs to overcome the rarity and heterogeneity of these tumors.

01 Apr 2026·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma

Article

Author: Zukov, Ruslan ; Abdrakhmanov, Ramil ; Kaidarova, Dilyara ; Baklanova, Olga ; Musaeva, Gunel ; Ongarbayev, Bakytzhan ; Tsimafeyeu, Ilya ; Petkau, Vladislav ; Chubenko, Vyacheslav ; Guliyev, Fuad

BACKGROUND:

Patterns of progression under immuno-oncology regimens in metastatic renal cell carcinoma (mRCC) remain poorly described. This study characterizes site-specific disease progression in patients receiving first-line dual immunotherapy or immunotargeted therapy.

METHODS:

This retrospective, observational cohort study included patients with clear-cell metastatic renal cell carcinoma treated between 2018 and 2024 with standard-dose regimens of nivolumab-ipilimumab (IO-IO) or pembrolizumab-axitinib and avelumab-axitinib combinations (IO-axitinib). The primary endpoint was the occurrence of new metastatic lesions at progression. Secondary endpoints included progression by >20% increase in target lesion size.

RESULTS:

Of 334 patients identified, 233 were evaluable for analysis. Radiographic progression occurred in 86.3% of IO-IO and 60% of IO-axitinib. Development of new metastatic lesions was more frequent with Nivo-Ipi (39.3% vs. 22.2%), most commonly involving the lungs and bones. In contrast, IO-axitinib combinations showed a greater propensity for progression through enlargement of pre-existing lesions (77.8% vs. 60.7%), accompanied by the emergence of new adrenal gland metastases. Across both treatment groups, lymph nodes emerged as the most frequent new site of disease progression.

CONCLUSIONS:

Nivo-Ipi was associated with more frequent development of new metastatic lesions, particularly in the lungs, bones, and lymph nodes, while axitinib-based combinations more often resulted in regrowth of existing disease with higher rates of adrenal involvement.

01 Mar 2026·MedComm

Tislelizumab Combined With Axitinib in Neoadjuvant Treatment of Locally Advanced Clear Cell Renal Cell Carcinoma: A Single‐Center, Phase II Clinical Study

Article

Author: Jiang, Bo ; Ji, Changwei ; Yang, Wenjin ; Zhang, Shun ; Zhang, Gutian ; Wang, Xin ; Liu, Guangxiang ; Guo, Hongqian ; Li, Hao

ABSTRACT:

Clear cell renal cell carcinoma (ccRCC) accounts for 70%‒80% of renal cell carcinoma cases and often shows no symptoms in early stages. Thus, approximately 30% of patients are diagnosed with advanced ccRCC. This single‐center prospective single‐arm study evaluated the efficacy and safety of tislelizumab combined with axitinib in patients with locally advanced ccRCC. A total of 20 eligible patients were enrolled at Nanjing Drum Tower Hospital from September 2021 to June 2024. The primary endpoint was objective response rate (ORR) before surgery, and secondary endpoints included disease‐free survival (DFS), overall survival, safety, and tissue biomarker analysis. All patients completed neoadjuvant treatment, and 19 underwent planned surgery; 70% (14/20) had cT3 stage disease with a median tumor diameter of 8.3 cm. The ORR was 55% (11 partial responses), 73.6% (14/19) achieved pathological downstaging, one patient attained pathological complete response, and no grade ≥3 perioperative complications occurred. The 2‐year DFS rate was approximately 90%, and biomarker analysis showed significantly higher tumor shrinkage rates in patients with RTK/RAS pathway alterations. In conclusion, tislelizumab combined with axitinib exhibits substantial efficacy and acceptable safety in neoadjuvant treatment of locally advanced ccRCC, providing preliminary clinical evidence for its application.

560

News (Medical) associated with Axitinib

01 Apr 2026

·www.globenewswire.com

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD). Upcoming Scientific Conferences: 14th Annual Vit-Buckle Society (VBS) Meeting: April 9 - 11, 2026Las Vegas, Nevada Symposium Title: Redefining the Management of Neovascular AMDSymposium Date/Time: Saturday, April 11, 2026, 1:15 – 2:00 PM PDTPresenters: Jeffrey S. Heier, MD, Chief Scientific Officer at Ocular Therapeutix, Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix, and Andrew A. Moshfeghi, MD, MBA, FASRS, USC Roski Eye Institute A copy of the VBS symposium presentation will be made available on Ocular’s website following the presentation on Saturday, April 11, 2026. Congreso Nacional de Oftalmologia (CNO) 2026: April 15 - 17, 2026Buenos Aires, Argentina Presentation Title: What are TKIs and What Do They Do?Session: SARyV: Macular Diseases (SARyV: Enfermedades maculares)Session Date/Time: Wednesday, April 15, 2026, 10:35 – 10:50 AM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Presentation Title: Current State of Treatment of Diabetic Retinal DiseaseSession: Current state of treatment of diabetic retinal diseaseSession Date/Time: Wednesday, April 15, 2026, 1:30 – 1:45 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Presentation Title: Current State of Treatment of Neovascular AMDSession: Wet AMD: The Debate (DMAE Húmeda: el debate)Session Date/Time: Wednesday, April 15, 2026, 3:45 – 4:00 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Exact medical conference presentation times may be subject to change. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Phase 3Phase 2

23 Mar 2026

·www.fiercepharma.com

EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race

EyePoint is asking the court to stop Ocular Therapeutix from sharing false and misleading statements about Duravyu’s clinical results and to force Ocular to issue an EyePoint-approved public retraction of its previous statements, in addition to a request for damages of an unspecified amount. A pair of rivals developing drugs for common retinal diseases are not seeing eye to eye.EyePoint on Friday filed a lawsuit in Massachusetts Superior Court accusing Ocular Therapeutix of engaging in a “malicious campaign” against EyePoint.EyePoint is currently developing the intravitreal insert Duravyu for wet age-related macular degeneration (AMD) and diabetic macular edema, while Ocular’s Axpaxli hydrogel is in phase 3 trials for wet AMD and diabetic retinopathy. Both companies have recently ramped up preparations for their anticipated launches by hiring commercial chiefs in the first weeks of 2026.In the lawsuit (PDF), EyePoint accused Ocular of attempting to “damage EyePoint’s reputation and cause it competitive harm by making blatantly false and defamatory statements” about both the company and Duravyu, with an alleged goal of improving Ocular and Axpaxli’s standing by comparison.In a statement sent to Fierce Pharma Marketing, Ocular painted the filing as an attack on its own drug, which it suggested “will cause significant competitive disruption to products on the market and in development for retinal vascular diseases.” “Remember, no other novel mechanism has ever demonstrated superiority to anti-VEGF in an FDA-aligned Phase 3 study,” the statement continued, pointing to recently released topline data in which Axpaxli outperformed Regeneron’s Eylea.“It is unfortunate that EyePoint has chosen to file a lawsuit against Ocular rather than answering the community’s questions about EyePoint’s own data and disclosures. We believe this is little more than an attempt to distract and detract from our successful Phase 3 superiority trial. Ultimately, we believe the data speak for themselves,” Ocular continued. “We stand by our statements and look forward to responding to EyePoint’s allegations in the course of the legal process.” EyePoint wrote in the lawsuit that Ocular has disseminated “false information, baseless rumors, and misleading claims” about EyePoint for years, but that it ramped up the alleged campaign last month.At that time, according to EyePoint, Ocular began sharing a “false and misleading” comparison of Duravyu and Axpaxli’s respective safety data in presentations, public comments and printed handouts.The comparison is allegedly based on “altered data, omitted information, and outright invented assertions” to make Axpaxli look comparatively safer than Duravyu, contrary to industry analysts’ conclusions. EyePoint said it has twice notified Ocular that its statements are false, but its competitor “has steadfastly refused to retract or correct its misinformation—and, indeed, it persists in disseminating it.”EyePoint is suing Ocular on counts of defamation, commercial disparagement, violations of Massachusetts’ consumer protection law and interference with EyePoint’s current and future business relations. The company is asking the court to stop Ocular from sharing false and misleading statements about Duravyu’s clinical results and to force Ocular to issue an EyePoint-approved public retraction of its previous statements, in addition to a request for damages of an unspecified amount.

Phase 3Patent Infringement

03 Mar 2026

·retinalphysician.com

Axpaxli Data Presented at Macula Society Meeting

At a symposium during the 49th meeting of the Macula Society in Coronado, California, Ocular Therapeutix presented detailed results from its phase 3 SOL-1 trial evaluating Axpaxli (OTX-TKI) for neovascular age-related macular degeneration (nAMD). The intravitreal insert met its primary endpoint and demonstrated superiority to aflibercept. The company said the results are intended to support a new drug application to the US Food and Drug Administration (FDA) through an accelerated pathway. SOL-1 enrolled 344 treatment-naïve patients and compared a single injection of Axpaxli, a bioresorbable hydrogel incorporating the tyrosine kinase inhibitor axitinib, with aflibercept 2 mg (Eylea; Regeneron) following an 8-week loading regimen. At week 36, 74.1% of Axpaxli-treated patients maintained vision, defined as loss of fewer than 15 ETDRS letters, compared with 55.8% in the aflibercept arm (risk difference, 17.5%; P=.0006). At week 52, 65.9% of Axpaxli-treated patients maintained vision vs 44.2% in the aflibercept arm (risk difference, 21.1%; P<.0001). Rescue-free rates and central subfield thickness control were also higher with Axpaxli through week 36. Safety findings were consistent with prior studies, with no treatment-related ocular serious adverse events reported. During the symposium, lead investigator Arshad M. Khanani, MD, said Axpaxli is the first investigational agent with a novel mechanism of action to demonstrate superiority over an approved anti-VEGF therapy in an FDA-aligned study in wet AMD. Additional presentations included Dilsher S. Dhoot, MD, who discussed real-world treatment challenges in nAMD; Peter K. Kaiser, MD, who reviewed the mechanism of action; Jeffrey S. Heier, MD, who outlined the trial design; and Patricio G. Schlottmann, MD, who presented safety data. Mark R. Barakat, MD, and Adnan Tufail, MBBS, MD, presented case examples and key insights. The symposium concluded with a panel discussion. The study was conducted under a special protocol assessment agreement. A second phase 3 trial, SOL-R, is ongoing, with topline results expected in the first half of 2027. Prior to the symposium, Pravin U. Dugel, MD, executive chairman, president, and CEO of Ocular Therapeutix, spoke with Retinal Physician about the trials, the regulatory pathway for Axpaxli, and what the results could mean for the future of wet AMD care. That interview is available here. RP

Clinical ResultPhase 3

100 Deals associated with Axitinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03218	Axitinib	L01XE17	DB06626

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Metastatic Renal Cell Carcinoma	China	Pfizer Europe MA EEIG	22 Apr 2025
Unresectable Renal Cell Carcinoma	China	Pfizer Europe MA EEIG	22 Apr 2025
Renal Cell Carcinoma	Japan	Pfizer Japan, Inc.	29 Jun 2012
Advanced Renal Cell Carcinoma	United States	PF Prism CV	27 Jan 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glycogen Storage Disease Type II	Phase 3	United States	Ocular Therapeutix, Inc.	01 Apr 2026
Nonproliferative diabetic retinopathy	Phase 3	United States	Ocular Therapeutix, Inc.	17 Nov 2025
Wet age-related macular degeneration	Phase 3	United States	Ocular Therapeutix, Inc.	29 Jan 2024
Wet age-related macular degeneration	Phase 3	Argentina	Ocular Therapeutix, Inc.	29 Jan 2024
Locally Advanced Renal Cell Carcinoma	Phase 3	-	Merck Sharp & Dohme LLC	16 Sep 2016
Advanced cancer	Phase 3	Germany	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	Italy	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	Spain	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	United Kingdom	Pfizer Inc.	01 Nov 2011
Neuroendocrine Carcinoma	Phase 3	Germany	Pfizer Inc.	01 Nov 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04698213 (Tide-A, ASCO_GU2026)	Phase 3	Metastatic Renal Cell Carcinoma	824	Intermittent Axitinib+Avelumab	cyhsvkkfqr(xqeafjiasl) = bovwewixld zubpvhmrpv (ytoaxjpkxh )	Negative	26 Feb 2026
ASCO_GU2026	Not Applicable	Renal Cell Carcinoma First line	632	Pembrolizumab-axitinib (PA)	zaobuycgvu(sdlkukhjyx) = lramcjlcia kzusupqnmd (hhdqhixxpq ) View more	Positive	26 Feb 2026
				Pembrolizumab-lenvatinib (PL)	zaobuycgvu(sdlkukhjyx) = aajygftcdn kzusupqnmd (hhdqhixxpq ) View more
NCT01744249 (AXINET, Pubmed \| J Clin Oncol)	Phase 3	Advanced Pancreatic Neuroendocrine Tumor Ki-67 index	256	Axitinib + Axitinibde LAR	nbowikxqdl(peowujxkvp) = zryrmetsvl egkkofsffc (wcdbmlazfc ) View more	Negative	20 Feb 2026
				Placebo + Octreotide LAR	nbowikxqdl(peowujxkvp) = iesyjvmupy egkkofsffc (wcdbmlazfc ) View more
NCT06223958 (SOL-1, Company_Website) Manual	Phase 3	Wet age-related macular degeneration	344	AXPAXLI 0.45mg	chjhkkzzrq(dzmukpomxl) = kwrhblobzd euooawzexg (axibkejual ) Met View more	Superior	17 Feb 2026
				aflibercept (2 mg)	chjhkkzzrq(dzmukpomxl) = jtyjjrcbtz euooawzexg (axibkejual ) Met View more
ESMO_ASIA2025	Not Applicable	Metastatic Renal Cell Carcinoma First line	194	IO-IO (nivolumab + ipilimumab)	teivzatexq(bowpqiqkwv) = xkgzhmnfiq axkbehrkfu (gvtcddfxcp, 1.0 - 55.9) View more	Positive	05 Dec 2025
				IO-TKI (pembrolizumab + axitinib or lenvatinib or nivolumab + cabozantinib)	teivzatexq(bowpqiqkwv) = qgxuaqduts axkbehrkfu (gvtcddfxcp, 1.0 - 45.2) View more
ASN2025	Not Applicable	Advanced Renal Cell Carcinoma First line	886	Axitinib plus Avelumab	sdhjluxfcw(ytyfztcgse) = nfczjxbymx pekawqctwr (mquzrossvr ) View more	Positive	08 Nov 2025
				Sunitinib	gnjxncvelu(cutgxpphdy) = rgagdrxzbs uhobxvlxpb (oprjaoezvi )
NCT04370509 (CTgov)	Phase 2	Metastatic Renal Cell Carcinoma \| Advanced Renal Cell Carcinoma \| Renal Cell Carcinoma ... View more	6	Cytoreductive Nephrectomy (CN)+Pembrolizumab	pvlngvtkew = xluppxvblz yrrevhubxk (qpnopazxxx, kmoleardvt - zbubqekrlv) View more	-	05 Nov 2025
NCT03990571 (ESMO2025)	Phase 2	Adenoid Cystic Carcinoma NOTCH1 mutations \| MYC upregulation \| TP63 upregulation	22	Axitinib plus Avelumab	vhnmhntawo(iyxrqrkjya) = yzwotzvmsa potsesucfz (awchftigsj )	Positive	17 Oct 2025
NCT02684006 (JAVELIN Renal 101, ESMO2025)	Phase 3	Renal Cell Carcinoma \| Non-Small Cell Lung Cancer	824	Atezolizumab	axmceubvdb(mjkqigfwek) = jtwezxsopf rjjbizsgnp (bwdimvbugf, 22 - 33)	Positive	17 Oct 2025
NCT02684006 (JAVELIN Renal 101, ESMO2025)	Phase 2/3	Metastatic Renal Cell Carcinoma sMAdCAM-1	1,051	Avelumab + Axitinib	bvlokctcyc(pkdciopxoz): HR = 0.59 (95.0% CI, 0.41 - 0.85), P-Value = 0.004 View more	Positive	17 Oct 2025
				Sunitinib